Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based CEO’ operating in the Therapeutics space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Alexander Isakov
Founder & CEO of Lattis Surgical
Follow Alexander Isakov:
About Lattis Surgical: The Lattis team developed a Contained Tissue Extraction (CTE) device, using bladeless technology.
Kevin Lee
Chief Executive Officer of Bicycle Therapeutics
Kevin Lee, Ph.D., MBA, is chief executive officer of Bicycle Therapeutics. Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programmes across the full spectrum of research and development, established Pfizer’s rare disease strategy, conceptualized and implemented the company’s gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK) and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, he lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions. Kevin studied pharmaceutical sciences at Nottingham University followed by a Ph.D. in pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, U.K. Kevin is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick.
Follow Kevin Lee:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Rachel E. Haurwitz
Co-founder, President & CEO of Caribou Biosciences
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
Follow Rachel E. Haurwitz:
About Caribou Biosciences: Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Simba Gill
President & CEO of Evelo Biosciences
Simba Gill, PhD is an entrepreneur, investor and CEO who believes passionately that science and globalization will dramatically improve life in the 21st century. Dr. Gill is currently the CEO of Evelo, Sr. Partner at Flagship Ventures, and Executive Chair of Blackfynn. Dr. Gill founded or had lead roles in moksha8, Epirus, Maxygen, Verdia, Avidia, Codexis, Systemix and Valentis, four of these companies have been taken public and three were acquired through strategic trade sales. Exit valuations were between $400M – $6B. Dr. Gill has also led, built and launched several commercial businesses/products generating annual revenues of between $150M-$2B. Dr. Gill has founded and/or had lead roles in pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, immunodiagnostics and the cancer microbiome. He has also been an investor, advisor, founder and CEO of several emerging market life science companies. Dr. Gill was a Partner at TPG, focused on investments in Life Sciences and Emerging Markets. Early in his career, Dr. Gill was co-head of Worldwide Marketing for Recormon. He also led corporate and market development and strategy from inception to commercialization of the Elecsys system, which became one of the world’s most widely used immunodiagnostic platforms. Dr. Gill served on the Board of Directors of the Tuberculosis Alliance, The Djerassi Resident Artists Program and the International Advisory Board of INSEAD. Dr. Gill was also the founder of Dispatches, an in-depth written and photojournalism periodical focused on key global issues. Dr. Gill has an MBA from INSEAD and carried out his PhD with focus on developing humanized antibodies to treat cancer. This work was done at King’s College, London in collaboration with the LMB at Cambridge and Celltech.
Follow Simba Gill:
About Epiva, Evelo Biosciences, moksha8 Pharmaceuticals, TPG Growth: Evelo Biosciences is dedicated to improving the lives of patients globally through the development of monoclonal microbials.
Aoife Brennan
CEO of Synlogic
Aoife Brennan joined Synlogic in September 2016 as chief medical officer and is responsible for the oversight and direction of the company’s clinical development strategy and operations. Aoife previously spent six years at Biogen, where she was in roles of increasing responsibility and most recently served as vice president and head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial. She has also led programs across multiple therapeutic areas including the late phase development of nusinersen for spinal muscular atrophy and ALPROLIX™ and ELOCTATE™, treatments for Hemophilia B and Hemophilia A. Prior to joining Biogen, she was director of clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes. Aoife holds a medical degree from Trinity College in Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
Follow Aoife Brennan:
About Synlogic: Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Liang Schweizer
Co-founder, President and CEO of HiFiBiO
Liang Schweizer is the Co-founder, President and CEO of HiFiBiO Therapeutics. Previously, she co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, Liang Schweizer was a director at Bristol-Myers Squibb Company, heading a group of scientists at Leads Discovery and Optimization (LDO), overseeing 60+ in vitro pharmacology projects across different therapeutic areas. Under her leadership, the team made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple BMS Immunoncology (IO) clinical candidates. Liang Schweizer graduated from the University of Science and Technology of China (USTC) majoring in Biology. She received her Master’s degree in Microbial Engineering at the University of Minnesota with minor in Chemical Engineering. Liang earned her Ph.D. in Molecular Biology from the University in Zurich, Switzerland. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC), New York.
Follow Liang Schweizer:
About HiFiBiO: HiFiBiO provides proprietary single cell technologies for applications in drug and biomarker discovery and development.
Michel Vounatsos
Chief Executive Officer of Biogen Idec
Michel Vounatsos is Executive Vice President and Chief Commercial Officer at Biogen. Michel brings extensive global biopharmaceutical experience and a track record of innovative stakeholder engagement to his leadership of the company’s commercial organization. Michel joined Biogen in 2016 after a 20 career at Merck, where he most recently served as President, Primary Care Business Line and Merck Customer Centricity. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups, and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers and retailers and the world’s largest governments. Michel previously held leadership positions across Europe and in China for Merck. Earlier in his career, Michel held management positions at Ciba-Geigy. Michel received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.
Follow Michel Vounatsos:
About Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Tony Coles
Chairman and CEO of Yumanity Therapeutics
Anthony Coles was named Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, in October 2014. Prior to this, from October 2013, Anthony Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately-held company. Anthony Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company (“Onyx”), from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer and a member of the board of directors of NPS Pharmaceuticals, Inc., a public biopharmaceutical company (“NPS”). Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Anthony Coles has been a director of the Company since April 2014. He is a member of the Compensation Committee and the Finance Committee.
Follow Tony Coles:
About Yumanity Therapeutics: Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases caused by protein misfolding.
Tom Henley
Founder and CEO of Empyrean Therapeutics
Tom Henley is the founder and CEO of Empyrean Therapeutics.
Follow Tom Henley:
About Empyrean Therapeutics: Empyrean Therapeutics develops next generation cell therapies to enable global and affordable cures for diseases.
Jason Fisherman
President & CEO of C4 Therapeutics
Follow Jason Fisherman:
About AlloMek Therapeutics, C4 Therapeutics: C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Hugh O’Dowd
President & CEO of Neon Therapeutics
Neon Therapeutics’ chief executive officer, Hugh O’Dowd, joined the company in 2016, bringing more than 20 years of expertise in pharmaceutical leadership and moving important oncology therapies from clinical development through commercialization. Hugh joined Neon Therapeutics from Novartis Oncology, where he spent more than 20 years in a variety of leadership roles, including chief commercial officer and head of global strategy. In this role, he was responsible for global commercialization for the oncology portfolio, including global brand leadership, health economics and pricing, early phase commercial development, strategic capabilities, business development, and licensing and global sales excellence. Hugh began his career in pharmaceuticals in 1992 at Glaxo in sales, and moved to Novartis in 1996. Following a career of increasing levels of responsibility in sales and marketing, he took a leading role in the commercialization of Gleevec, and assumed country- and region-level commercial leadership roles before overseeing the entirety of Novartis Oncology commercialization and strategy in 2011. Since 2015, Hugh was country president and general manager of Novartis in the United Kingdom and Ireland. Hugh holds a B.A. from Loyola University Chicago, and an MBA from the Kellstadt Graduate School of Business at DePaul University Chicago.
Follow Hugh O’Dowd:
About Neon Therapeutics: NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
John Leonard
President , Chief Executive Officer & Member Board of Directors of Intellia Therapeutics
After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality. John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research. In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of QuintilesIMS (NYSE:Q) and Chimerix (Nasdaq:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.
Follow John Leonard:
About Intellia Therapeutics: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Nagesh K. Mahanthappa
CEO of Scholar Rock
Nagesh Mahanthappa is a biotechnology entrepreneur with over 20 years of industry experience in roles spanning discovery research through early clinical development, as well as operations and strategy. Prior to Scholar Rock, Nagesh Mahanthappa was a founding employee and VP, Corporate Development at Avila Therapeutics, Inc. (acquired by Celgene Corporation in 2012). Avila discovered and developed novel covalent drugs for the treatment of cancer, autoimmune, and viral diseases. He was previously a founding employee of Alnylam Pharmaceuticals, the first biotech established to discover RNA interference therapeutics and rose to VP, Scientific & Strategic Development. Earlier professional roles include business development at Vertex Pharmaceuticals, and discovery research at Ontogeny (now Curis, Inc.) and Cambridge NeuroScience. He was also a founder of TwistDx, a DNA diagnostics company acquired by Inverness Medical Innovations (now Alere, Inc.) in 2010. Nagesh Mahanthappa received his Ph.D. in Neurobiology from the California Institute of Technology, and post-doctoral training at the E.K. Shriver Center for Mental Retardation (then affiliated with Massachusetts General Hospital) and Harvard Medical School. He received his MBA from the F.W. Olin Graduate School of Management at Babson College.
Follow Nagesh K. Mahanthappa:
About Scholar Rock: Scholar Rock is discovering and developing a new class of biologic therapies.
John Evans
CEO of Beam Therapeutics
Follow John Evans:
About ARCH Venture Partners, Beam Therapeutics: Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Richie Bavasso
Founder and CEO of nQ Medical
Mr. Bavasso is one of the early pioneers of use of digital media, devices and the web as tools to support pharmaceutical sales and marketing strategies and tactics. Since 1999, he has worked with top 25 Pharma clients globally to introduce the Closed Loop Marketing (CLM) function. He has set procedure and precedent in the areas of sales force effectiveness, business-rule driven content management, multichannel marketing, and mobile technology. A frequent speaker at industry conferences and events, Mr. Bavasso serves as an advocate for the industry in promoting digital conversation as integral to the various enterprise functions within pharma and the medical community. Prior to his seven years as co-founder and President of Exploria SPS, Mr. Bavasso served for sixteen years as CEO of Pharmedica Holdings, LLC, and President of its INFLUENT Division, at the time one of the largest medical education companies in the world. He built Pharmedica holdings from its start as a meetings planning company in 1992, doubling its revenues each year until its sale in 2001. This growth included an ACCME accredited entity (Center for Medical Education, LLC), a digital content division (Influent, LLC), and a call center (ContextMedicus, LLC). He opened offices in California, Connecticut, Illinois, and North Carolina. After his three-year earn out, Bavasso partnered to co-found Exploria SPS, LLC, as the mobile devices division of Exploria, Inc. Within three years, Exploria SPS became the market leader for CLM with offices in Connecticut and France and currently licenses software in 33 countries and 18 languages. Mr. Bavasso’s introduction of CLM and subsequent influence over the growth and expansion of CLM globally led to his recognition in 2007, by PharmaVoice magazine as one of the top 100 most influential people in pharma. Foreseeing the trends in Pharma that have impacted its selling model and the changing influence dynamic of payors on prescribing, Mr. Bavasso incubated a new and disruptive concept meant to serve as the transaction-fed, new marketplace for healthcare. This led to the incorporation of RIMEDIO, Inc. in October 2012 intent on reshaping the dynamic of how healthcare interacts and transacts to achieve mutual stakeholder objectives. RIMEDIO leverages the power of social utilities with eCommerce, content management and communications tools to consummate transactions between healthcare stakeholders. He is currently co-founder and CEO of nQ Medical, Inc., a machine learning computational biomarker company leveraging keyboard data to manage neuromotor diseases. Everyone has a unique typing signature. Research has revealed that the way we interact with computers and mobile devices can reveal with startling accuracy the presence of certain neuro-motor diseases. This Massachusetts Institute of Technology discovered/Michael J. Fox Foundation validated artificial intelligence tool (neuroQWERTY) has opened a broad opportunity to better diagnose diseases, track disease progression, and monitor medication effectiveness and symptoms. Mr. Bavasso is also a licensed hospital administrator having served from 1981 to 1992 leading two health care systems in New England. A graduate of Pepperdine University, Malibu, CA, with a Bachelor of Science degree in business administration, he received his MBA in health care management and finance from Bryant University, Smithfield, RI.
Follow Richie Bavasso:
About nQ Medical: nQ Medical is a neurotechnology company allowing Data Defined Disease Management via digital biomarkers using AI.
Diego Miralles
CEO of Vividion Therapeutics
Diego Miralles is the Chief Executive Officer at Vividion Therapeutics.
Follow Diego Miralles:
About Flagship Pioneering, Laronde, Vividion Therapeutics: Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.
Steven L. Hoerter
President and CEO of Deciphera Pharmaceuticals
Steven L. Hoerter has served as our Senior Vice President, Commercial since August 2011. From 2010 to 2011, Steven Hoerter was General Manager and Management Center Head at F. Hoffmann-La Roche Ltd. for the Sub-Saharan Africa and Indian Ocean Region, based in Johannesburg, South Africa. From 2005 to 2010, Steven Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business as Senior Director, Pipeline Development and Commercial Operations. Prior to that he worked at Chiron Corporation and Eli Lilly and Company. During Steven Hoerter’s 11-year career at Lilly, he held positions in sales, business development, marketing and business unit management in the US, Europe and Africa. Steven Hoerter has a B.A. in Russian and Political Science from Bucknell University, an M.B.A. from Tilburg University and a M.S. in Management from Purdue University.
Follow Steven L. Hoerter:
About Deciphera Pharmaceuticals: Deciphera Pharmaceuticals focuses on improving kinase inhibitor treatments.
David R. Elmaleh
Scientific Founder, CEO and Chairman of AZTherapies
David R. Elmaleh is the founder of [Mersana Therapeutics](https://www.crunchbase.com/organization/mersana-therapeutics#/entity). Previously, he served as the chairman and president of AZTherapies. Elmaleh obtained a bachelor’s degree in chemistry and physics, and master’s degree and PhD in organic chemistry from Hebrew University.
Follow David R. Elmaleh:
About AZTherapies, Mersana Therapeutics: AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Donald Nicholson
CEO of Nimbus Therapeutics
Follow Donald Nicholson:
About Nimbus Therapeutics: Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
Heather Fairhead
Founder & CEO of Phico Therapeutics
Dr Fairhead has over 17 years’ experience directing research teams in a variety of disciplines and has led Phico in developing SASPject technology from a concept through a Phase I clinical trial. Prior to her scientific career, Heather worked for 10 years in sales and marketing in a wide range of industries.
Follow Heather Fairhead:
About Phico Therapeutics: Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
George Foot
Co-Founder & Co-CEO of Sixfold Bioscience
George Foot is the Co-Founder & Co-CEO at Sixfold Bioscience.
Follow George Foot:
About Sixfold Bioscience: Sixfold Bioscience develops and researches on biotechnology advances for RNA therapies.
Jason Gardner
CEO, President & Co-Founder of Magenta Therapeutics
Jason is CEO, President and Cofounder of Magenta Therapeutics, a biotechnology company created to transform stem cell transplantation. He joined Atlas Venture as an Entrepreneur-in-Residence to create Magenta, working with Third Rock Ventures. He has held leadership roles in pharma and biotech over 18 years, where he most recently established and ran the GSK R&D Satellite in Boston. He also created and led the Regenerative Medicine Discovery Performance Unit, a global team across R&D that established the stem cell gene therapy programs in pharma and ran multiple collaborations. Jason joined GSK in 2005 following eight years in the biotech arena to become a member of the lapatinib clinical team that led to the successful new drug application file for Tykerb in breast cancer in 2007. He then joined the CEEDD, later leading Research and Alliance Management, where new alliances were established with multiple biotech companies. In 2009, he created the Stem Cell DPU to deliver on the therapeutic and platform promise in regenerative medicine. Under his stewardship, the stem cell gene therapy alliance was formed with Fondazione Telethon, one of the biggest biomedical charitable foundations in Italy, and GSK’s Rare Disease Unit, and the team spearheaded GSK’s collaboration with the Harvard Stem Cell Institute. Jason was educated at Cambridge University where he received B.A. and M.A. degrees in Natural Sciences. He completed his Ph.D. at Oxford University and was a Research Fellow in Medicine at Harvard University.
Follow Jason Gardner:
About Magenta Therapeutics: Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
Alexis C. Wallace
President and Chief Executive Officer, Director and Co-founder of Thrombolytic Science International
Alexis Wallace has over 20 years of international business development and operational experience, including more than two decades with leading biopharmaceutical companies and ventures. Prior to joining TSI, Mr. Wallace was Executive Director of Medicine in Need, a not-for-profit biotechnology company funded by the Bill and Melinda Gates Foundation. There, Mr. Wallace oversaw the development of an inhaled version of an anti-tuberculosis drug from pre-IND through phase I human clinical trials. Mr. Wallace was also a Principal in the Business Development arm of Puretech Ventures, where he created and grew the company’s European business. Mr. Wallace also served as the Director of Science Strategy at Genzyme Corporation, where he was instrumental in the establishment of major joint ventures resulting in three commercialized products. Mr. Wallace holds an undergraduate degree in Life Sciences from Université Pierre et Marie Curie, Paris, France; an MScEng in Organic Chemistry from École Supérieure de Chimie Industrielle de Lyon, France; and an MBA from the Tuck Business School at Dartmouth College. Mr. Wallace is a member of the Board of Directors of the Vascular Laboratory, Inc.
Follow Alexis C. Wallace:
About Thrombolytic Science International: Thrombolytic Science International develops a clot-dissolving therapy for stroke and other thrombotic diseases.
Rod Richards
Founder, CEO of VHSquared
Follow Rod Richards:
About VHSquared: VHsquared is dedicated to the development of novel antibody domains engineered to be stable in the GI tract.
Huw Jones
Chief Executive Officer & Executive Chairman of Chronos Therapeutics
Follow Huw Jones:
About Chronos Therapeutics, Evgen Pharma: Chronos Therapeutics is a drug development company focused on the development of drugs for the treatment of age-related diseases.
Gleb Kuznetsov
Co-Founder and CEO of Manifold Bio
Gleb Kuznetsov is the Co-Founder and CEO at Manifold Bio.
Follow Gleb Kuznetsov:
About Manifold Bio: Manifold Bio is building a protein barcoding platform to bring the power of multiplexed measurement.
Billy Boyle
CEO and Co-Founder of Owlstone Nanotech
Since co-founding Owlstone, Billy has been overseeing the development and implementation of the detection technology with nanotechnology foundry partners. He is also active in business development, demonstrating to partners how the Owlstone technology can used to realise a paradigm shift in detection applications and deployment scenarios. Billy is heavily involved in the creation and realisation of new technologies and IP. Prior to joining Owlstone Billy was a Research Associate in the Microsystems and Nanotech group at Cambridge University. In an academic / industry consortium he designed and developed silicon-opto hybrid devices for next generation telecoms systems.
Follow Billy Boyle:
About Owlstone Nanotech: OWLSTONE is a platform technology, where regardless of the application, hardware remains the same & the app is enabled through software.
Matthew Gregory
Chief Executive Officer of Isomerase Therapeutics
Matthew is an experienced drug discovery professional skilled in programme management and intellectual property rights protection. He has particular experience of anti-infective drug discovery and was previously Director of Intellectual Property and Project Management at Biotica Technology Ltd. At Biotica he managed the intellectual property and collaborative research on internal projects from 2005-2013, with particular therapeutic focus in infectious diseases, inflammation and oncology. In doing so, he was also responsible for segregating internal programmes from collaborative research. Matthew was the project leader of the company’s flagship cyclophilin inhibitor program, which was focused on development of a high barrier to resistance backbone therapy for treatment of HCV, HBV and HIV. Matthew joined Biotica in 2003, having been involved with the company since 1999 when he was at the University of Cambridge working on production of novel rapamycin analogues and genetic manipulation of the biosynthetic pathway in Professor Peter Leadlay’s group. Matthew has almost 20 years of experience in actinomycete genetics, is an author or inventor on over 30 patents, patent applications or publications and holds a BSc in Biochemistry and Genetics and a PhD in Molecular Genetics from the University of Nottingham.
Follow Matthew Gregory:
About Isomerase Therapeutics: Isomerase Therapeutics is an agile drug discovery and development company.
Jim Huntington
CEO of ApcinteX
Jim Huntington joined APCINTEX as CEO in 2018.
Follow Jim Huntington:
About ApcinteX, University of Cambridge: ApcinteX develops and markets anticoagulant APC pathway to treat haemophilia.
